| Characterization of mismatch‐repair/microsatellite instability‐discordant endometrial cancers CJ Riedinger, A Esnakula, PJ Haight, AA Suarez, W Chen, J Gillespie, ... Cancer 130 (3), 385-399, 2024 | 22 | 2024 |
| The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria PJ Haight, CJ Riedinger, FJ Backes, DM O'Malley, CM Cosgrove Gynecologic Oncology 175, 32-40, 2023 | 17 | 2023 |
| TP53 mutation and abnormal p53 expression in endometrial cancer: associations with race and outcomes K Whelan, M Dillon, KC Strickland, B Pothuri, V Bae-Jump, LE Borden, ... Gynecologic oncology 178, 44-53, 2023 | 16 | 2023 |
| Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis DA Barrington, PJ Haight, C Calhoun, C Tubbs, DE Cohn, KL Bixel Gynecologic Oncology 162 (3), 626-630, 2021 | 16 | 2021 |
| Lateral thoracotomy for epicardial pacemaker placement in patients with congenital heart disease PJ Haight, RE Stewart, EV Saarel, GB Pettersson, HK Najm, PF Aziz Interactive CardioVascular and Thoracic Surgery 26 (5), 845-851, 2018 | 16 | 2018 |
| Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis DA Barrington, C Riedinger, PJ Haight, C Tubbs, DE Cohn Gynecologic Oncology 165 (3), 500-505, 2022 | 14 | 2022 |
| Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population PJ Haight, DA Barrington, SM Graves, RN Piver, J Baek, M Ardizzone, ... Gynecologic Oncology 170, 203-209, 2023 | 6 | 2023 |
| “More than a song and dance”: Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok M Morton, PJ Haight, W Khadraoui, F Backes, K Bixel, DM O'Malley, ... Gynecologic Oncology 175, 81-87, 2023 | 5 | 2023 |
| Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer CJ Riedinger, M Brown, PJ Haight, FJ Backes, DE Cohn, PJ Goodfellow, ... Frontiers in Oncology 13, 1147657, 2023 | 5 | 2023 |
| The poor prognosis of sarcomatoid carcinoma arising from low grade serous ovarian cancer: A case report and review of the literature P Haight, J Savage, K Bixel Gynecologic Oncology Reports 36, 100735, 2021 | 5 | 2021 |
| Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II? MD Levine, DM O'Malley, PJ Haight, L Senter, V Wagner, KL Bixel, ... Gynecologic oncology reports 46, 101173, 2023 | 4 | 2023 |
| Learning to lead: The evolution of a pilot leadership curriculum for gynecologic oncology fellows at the Ohio State University MD Levine, VM Wagner, CJ Riedinger, W Khadraoui, PJ Haight, M Morton, ... Gynecologic Oncology Reports, 101327, 2024 | 3 | 2024 |
| Cervical carcinoma with histologic components of sarcomatoid carcinoma and multiple basaloid variants: A case report and review of the literature PJ Haight, AV Castaneda, JM Savage, LJ Copeland Gynecologic Oncology Reports 37, 100797, 2021 | 2 | 2021 |
| Don't lose your pants*: Telehealth strategies for maintaining revenue streams in a gynecologic oncology practice during a global pandemic*(Pants recommended for all televisits) D Barrington, C Calo, P Haight, D Cohn Gynecologic Oncology 162, S143-S144, 2021 | 2 | 2021 |
| Timing of Repeat Cesarean Delivery for Women with a Prior Classical Incision M Ma'Ayeh, P Haight, EA Oliver, MB Landon, KM Rood American Journal of Perinatology 38 (06), 529-534, 2021 | 2 | 2021 |
| Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer CJ Riedinger, DA Barrington, CI Nagel, WK Khadraoui, PJ Haight, ... Gynecologic oncology 183, 78-84, 2024 | 1 | 2024 |
| Authentic leadership in action: Experience gained from a gynecologic oncology fellowship leadership curriculum MD Levine, VM Wagner, CJ Riedinger, W Khadraoui, PJ Haight, M Morton, ... Gynecologic Oncology 182, 176-178, 2024 | 1 | 2024 |
| Platinum-Free Interval and Response to Platinum Retreatment or Lenvatinib/Pembrolizumab in Patients with Recurrent Endometrial Cancer: A Real-World Endometrial Cancer … P Haight, M Sanchez, S Thomas, C Smitherman, C Cosgrove, ... | 1 | 2024 |
| PR023/# 503 Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and … B Corr, S Thomas, P Haight, E Stock, J Floyd, L Borden, I Tunnage, ... International Journal of Gynecologic Cancer 33 (Suppl 4), 2023 | 1 | 2023 |
| The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer PJ Haight, Q Kistenfeger, CJ Riedinger, W Khadraoui, FJ Backes, ... Gynecologic Oncology 178, 14-22, 2023 | 1 | 2023 |
